Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. 12 July 2019. Carlos Nunez.

Executive Summary

A new multinational study by sleep device-maker ResMed and 12 academic leaders in sleep research found that nearly one billion people worldwide have sleep apnea, about 10 times higher than previous estimates by the World Health Organization. See what study co-author and ResMed's CMO, Carlos Nunez, said about it here.

"Many will attribute the resulting tiredness to aging or stress. Others will mention the problem to their doctor, only to be misdiagnosed with insomnia, migraines, chronic fatigue or other conditions. Misdiagnosis is especially common in women, since sleep apnea was long thought to be much more common in men." – Carlos Nunez, CMO, ResMed

Find out more: ResMed Study Claims Nearly One Billion People Worldwide Have Sleep Apnea

Click here for a free trial of Medtech Insight

Advertisement

Related Content

ResMed Study Claims Nearly A Billion People Worldwide Have Sleep Apnea

Topics

Advertisement
UsernamePublicRestriction

Register

MT125355

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel